ZFNs and TALENs were successfully used to knock-out TCRα constant (TRAC) and TCRβ constant (TRBC) to generate TCR-negative CAR T cells to prevent GVHD without compromising CAR-mediated cytotoxicity [37,38]. Here, TRAC is linked to graft versus host disease.